Toceranib 是口服具有活力的受体酪氨酸激酶 (RTK) 抑制剂，能有效抑制PDGFR，VEGFR，Kit，抑制 PDGFRβ 和 Flk-1/KDR 的Ki分别为 5 nM 和 6 nM。它具有抗肿瘤和抗血管生成作用，用于研究犬肥大细胞肿瘤。

Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.

Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment[1].

356068-94-5

C22H25FN4O2

396.46

托西尼布;SU11654;PHA 291639E

DMSO:2.4 mg/mL (6.05 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years